Alumis to Present at Leerink Healthcare Conference

Got story updates? Submit your updates here. ›

Alumis Inc., a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, announced that its President and CEO Martin Babler will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026.

Why it matters

As a clinical-stage biopharma company, Alumis' participation in high-profile industry conferences provides an opportunity to showcase its pipeline of innovative immune-focused therapies to potential investors and partners as it works to advance its drug candidates through late-stage trials.

The details

Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib for immune disorders like psoriasis and lupus, as well as a subcutaneously delivered anti-IGF-1 receptor therapy called lonigutamab for thyroid eye disease. The company will provide an overview of its programs and progress during the Leerink Partners conference fireside chat.

• The conference presentation is scheduled for Monday, March 9, 2026 at 10:40 a.m. ET.

What’s next

Alumis will provide an overview of its pipeline of targeted immune therapies during the Leerink Partners conference fireside chat on March 9, 2026.